Nothing Special   »   [go: up one dir, main page]

CY1120475T1 - Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα - Google Patents

Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα

Info

Publication number
CY1120475T1
CY1120475T1 CY20181100757T CY181100757T CY1120475T1 CY 1120475 T1 CY1120475 T1 CY 1120475T1 CY 20181100757 T CY20181100757 T CY 20181100757T CY 181100757 T CY181100757 T CY 181100757T CY 1120475 T1 CY1120475 T1 CY 1120475T1
Authority
CY
Cyprus
Prior art keywords
indoli
pyrrolium
producers
preparing
new
Prior art date
Application number
CY20181100757T
Other languages
English (en)
Inventor
Patrick Casara
Thierry Le Diguarher
Jean-Michel Henlin
Jérôme-Benoît STARCK
Arnaud Le Tiran
Guillaume De Nanteuil
Olivier Geneste
James Edward Paul Davidson
James Brooke MURRAY
I-Jen Chen
Claire WALMSLEY
Christopher John GRAHAM
Stuart Ray
Daniel MADDOX
Simon Bedford
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of CY1120475T1 publication Critical patent/CY1120475T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)

Abstract

Ενώσεις του τύπου (I), όπου Ra, Rb, Rc, Rd, R3, R4, R5, A1, A2, Τ και W είναι όπως ορίζονται στην περιγραφή. Φάρμακα.
CY20181100757T 2013-07-23 2018-07-19 Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα CY1120475T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357277A FR3008978A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
PCT/FR2014/051884 WO2015011396A1 (fr) 2013-07-23 2014-07-22 Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
CY1120475T1 true CY1120475T1 (el) 2019-07-10

Family

ID=49911607

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100757T CY1120475T1 (el) 2013-07-23 2018-07-19 Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα

Country Status (31)

Country Link
US (2) US9765056B2 (el)
EP (2) EP3168217A1 (el)
JP (1) JP6458028B2 (el)
KR (1) KR102337149B1 (el)
CN (1) CN105408321B (el)
AR (1) AR099914A1 (el)
AU (1) AU2014294866B2 (el)
BR (1) BR112016001333B1 (el)
CA (1) CA2917965C (el)
CY (1) CY1120475T1 (el)
DK (1) DK3027602T3 (el)
EA (1) EA028609B1 (el)
ES (1) ES2687475T3 (el)
FR (1) FR3008978A1 (el)
HK (1) HK1218753A1 (el)
HR (1) HRP20181333T1 (el)
HU (1) HUE039507T2 (el)
LT (1) LT3027602T (el)
MX (1) MX364479B (el)
NZ (1) NZ715847A (el)
PL (1) PL3027602T3 (el)
PT (1) PT3027602T (el)
RS (1) RS57545B1 (el)
RU (1) RU2693404C2 (el)
SG (1) SG11201600004SA (el)
SI (1) SI3027602T1 (el)
TW (1) TW201504224A (el)
UA (1) UA117020C2 (el)
UY (1) UY35653A (el)
WO (1) WO2015011396A1 (el)
ZA (1) ZA201600415B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237509A (zh) * 2015-11-20 2016-01-13 江苏瑞邦农药厂有限公司 一种2,2-二氟-1,3-苯并二恶茂的合成方法
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN116462666A (zh) 2017-01-10 2023-07-21 瑞士苏黎世联邦理工学院 细胞保护性化合物及其用途
TWI743346B (zh) 2017-03-31 2021-10-21 國立大學法人東京大學 諾羅病毒抗體
CN108409580A (zh) * 2018-02-01 2018-08-17 浙江工业大学 一种苄胺类化合物的合成方法
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
AR129380A1 (es) 2022-05-20 2024-08-21 Novartis Ag Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509104A (ja) 2003-10-24 2007-04-12 グラクソ グループ リミテッド 複素環式化合物
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US8557812B2 (en) * 2004-08-20 2013-10-15 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
GB0522908D0 (en) 2005-11-10 2005-12-21 Merck Sharp & Dohme Therapeutic agents
EP2714681B1 (en) * 2011-05-25 2015-06-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
US20140357666A1 (en) * 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
WO2013096059A1 (en) * 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
BR112014015339A8 (pt) * 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com parceiros de ligação
KR20140107578A (ko) * 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
MX2014007729A (es) * 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
NZ715847A (en) 2019-06-28
SG11201600004SA (en) 2016-02-26
UA117020C2 (uk) 2018-06-11
AU2014294866B2 (en) 2018-09-27
HK1218753A1 (zh) 2017-03-10
HRP20181333T1 (hr) 2018-10-19
SI3027602T1 (en) 2018-08-31
KR20160034384A (ko) 2016-03-29
DK3027602T3 (en) 2018-09-24
AR099914A1 (es) 2016-08-31
WO2015011396A1 (fr) 2015-01-29
JP6458028B2 (ja) 2019-01-23
MX364479B (es) 2019-04-29
LT3027602T (lt) 2018-07-25
RU2016106002A3 (el) 2018-03-19
CN105408321B (zh) 2019-03-08
KR102337149B1 (ko) 2021-12-07
FR3008978A1 (fr) 2015-01-30
HUE039507T2 (hu) 2019-01-28
CA2917965C (fr) 2018-03-06
BR112016001333B1 (pt) 2022-03-03
RS57545B1 (sr) 2018-10-31
US20170342051A1 (en) 2017-11-30
US20160152599A1 (en) 2016-06-02
PT3027602T (pt) 2018-07-23
PL3027602T3 (pl) 2018-10-31
MX2016000900A (es) 2016-05-05
AU2014294866A1 (en) 2016-02-04
EA201600121A1 (ru) 2016-07-29
UY35653A (es) 2015-02-27
ZA201600415B (en) 2017-03-29
EP3027602A1 (fr) 2016-06-08
RU2016106002A (ru) 2017-08-30
CN105408321A (zh) 2016-03-16
JP2016531108A (ja) 2016-10-06
RU2693404C2 (ru) 2019-07-02
TW201504224A (zh) 2015-02-01
BR112016001333A2 (el) 2017-07-25
US10662173B2 (en) 2020-05-26
CA2917965A1 (fr) 2015-01-29
EP3027602B1 (fr) 2018-06-13
US9765056B2 (en) 2017-09-19
EA028609B1 (ru) 2017-12-29
EP3168217A1 (fr) 2017-05-17
ES2687475T3 (es) 2018-10-25

Similar Documents

Publication Publication Date Title
CY1120475T1 (el) Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1123645T1 (el) Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1119652T1 (el) Νεα παραγωγα ινδολιζινης, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν
CY1118756T1 (el) Νεα παραγωγα πυρρολιου, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν
CY1118547T1 (el) Νεα παραγωγα ινδολιζινης, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν για τη θεραπεια του καρκινου
CY1118058T1 (el) Νεα παραγωγα θειενοπυριμιδινης, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1122560T1 (el) Νεα παραγωγα αμμωνιου, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουναυτα
CY1123069T1 (el) Νεα (ετερο)αρυλ-υποκατεστημενα-πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1120991T1 (el) Νεα παραγωγα αμινοξεος, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1122542T1 (el) Νεα παραγωγα υδροξυεστερα, μια διεργασια για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
CY1122870T1 (el) Νεα πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CY1120474T1 (el) Χημικες ενωσεις
CY1119953T1 (el) Yποκατεστημενες πυριδοπυραζινες ως προτυποι syk ανοστολεις
DK3518892T5 (da) Farmaceutisk formulering, der indeholder en insulinforbindelse
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
CY1121247T1 (el) Νεες ενωσεις ισοϊνδολινης ή ισοκινολινης, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτες
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
HUP1300646A2 (en) Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов
IN2013MU00665A (el)
DK3081560T3 (da) Taxanforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf